Log In


Dual antithrombotic therapy after percutaneous coronary intervention

Watch Dr Christopher Cannon discuss his study: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation


In patients with atrial fibrillation who have had a percutaneous coronary intervention, the current standard practice is to prescribe “triple therapy” i.e. warfarin plus two antiplatelet agents including an aspirin. However, this is associated with a high risk of bleeding. This ground-breaking trial compares triple therapy with “dual therapy” (dabigatran plus one antiplatelet agent).

Target audience

This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.

Learning objective

After this activity, participants should be able to:

  • Describe outcomes from new data regarding the impact on bleeding and thrombotic events of dual therapy with dabigatran and a P2Y12 inhibitor as compared with triple therapy with warfarin,  a P2Y12 inhibitor and aspirin in this patient population


This independent educational activity by NOAC Education is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.


John Camm
St George’s, University of London
Professor of Clinical Cardiology at St. George's Hospital Medical School in London
Christopher Cannon
Baim Institute for Clinical Research, Massachusetts, USA
Professor of medicine at Harvard Medical School